Log in to save to my catalogue

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adeno...

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adeno...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1473891640

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

About this item

Full title

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Publisher

Kidlington: Elsevier Ltd

Journal title

The Lancet (British edition), 2014-01, Vol.383 (9911), p.31-39

Language

English

Formats

Publication information

Publisher

Kidlington: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, prolonged survival in patients with advanced gastric cancer. Methods W...

Alternative Titles

Full title

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1473891640

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1473891640

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(13)61719-5

How to access this item